• 1. Enthalpy of interaction between some cationic polypeptides and n-alkyl sulphates in aqueous solution
  Maria I. Paz-Andrade,Malcolm N. Jones,Henry A. Skinner J. Chem. Soc. Faraday Trans. 1 1978 74 2923
• 2. Temperature dependence of the pitch in chiral lyotropic chromonic liquid crystals
  Timothy Ogolla,Robert S. Paley,Peter J. Collings Soft Matter 2019 15 109
• 3. Temperature dependence of the pitch in chiral lyotropic chromonic liquid crystals
  Timothy Ogolla,Robert S. Paley,Peter J. Collings Soft Matter 2019 15 109
• 4. Interfacial electrostatics of poly(vinylamine hydrochloride), poly(diallyldimethylammonium chloride), poly-l-lysine, and poly-l-arginine interacting with lipid bilayers
  A. C. McGeachy,N. Dalchand,E. R. Caudill,T. Li,M. Do?angün,L. L. Olenick,H. Chang,J. A. Pedersen,F. M. Geiger Phys. Chem. Chem. Phys. 2018 20 10846
• 5. Mixtures of oppositely charged polypeptides as high-performance dispersing agents for single-wall carbon nanotubes
  Gordon K.-C. Lee,Clare Sach,Malcolm L. H. Green,Luet-lok Wong,Christoph G. Salzmann Chem. Commun. 2010 46 7013

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

DL-Arginine Hydrochloride (CAS No. 15595-35-4): A Multifunctional Compound in Chemical and Biomedical Research

The DL-arginine hydrochloride, chemically characterized by the CAS No. 15595-35-4, is a critical compound in both academic and industrial applications. This DL-isomer of arginine hydrochloride combines the structural versatility of arginine with the solubility-enhancing properties of its hydrochloride salt form. Recent advancements in synthetic chemistry and pharmacology have further highlighted its role in drug delivery systems, metabolic pathway modulation, and biomaterial design. Its molecular formula, C₆H₁₄N₄O₂HCl, underscores its amino acid-derived backbone with a chloride counterion, enabling diverse functionalization pathways.

In biomedical research, the CAS 15595-35-4 compound has emerged as a pivotal tool for studying nitric oxide (NO) biosynthesis. A 2023 study published in Nature Communications demonstrated that DL-arginine hydrochloride supplementation enhances endothelial NO production in vitro, offering therapeutic potential for cardiovascular disorders such as hypertension and ischemic heart disease. The compound’s ability to cross biological membranes efficiently makes it particularly valuable for targeted delivery systems compared to L-arginine alone, as shown in recent lipid nanoparticle formulations for gene therapy.

The synthesis of DL-arginine hydrochloride involves a two-step process: first, the preparation of arginine via Strecker synthesis or enzymatic methods, followed by neutralization with hydrochloric acid to form the salt. Innovations in green chemistry have led to solvent-free protocols using microwave-assisted reactions reported in the Journal of Chemical Technology & Biotechnology, achieving >98% purity with reduced environmental footprint. These advancements align with current industry trends toward sustainable manufacturing practices while maintaining compliance with pharmaceutical grade standards.

In cancer research, this compound has gained attention for its dual roles as both a chemopreventive agent and a radiosensitizer. A phase II clinical trial (NCT04876219) recently revealed that combining DL-arginine hydrochloride with conventional chemotherapy improved tumor oxygenation levels by 37%, enhancing radiation efficacy in head and neck cancers. The mechanism involves arginine’s role as a substrate for arginase enzymes expressed by tumor-associated macrophages, creating localized citrulline gradients that disrupt hypoxic microenvironments.

Beyond therapeutic applications, the CAS No. 15595-35-4 material is integral to advanced biomaterials engineering. Researchers at MIT’s Koch Institute demonstrated its use as a crosslinking agent for hyaluronic acid-based hydrogels, creating matrices that promote vascular endothelial growth factor (VEGF) release profiles mimicking physiological angiogenesis patterns. Such systems are now being tested for ischemic limb regeneration therapies, showcasing the compound’s transition from basic chemistry to clinical innovation.

In sports science applications, recent metabolomics studies using LC-MRM/MS techniques have quantified how oral administration of DL arginine hydrochloride increases plasma symmetric dimethylarginine (SDMA) levels by modulating dimethylarginine dimethylaminohydrolase (DDAH) activity. This discovery provides new insights into ergogenic aid development while emphasizing the need for personalized dosing regimens based on individual renal function parameters.

The structural flexibility of this compound allows it to form stable complexes with transition metals such as copper(II), creating novel chelates with antioxidant properties. A 2024 study from Angewandte Chemie highlighted copper(II)-DLA complexes’ ability to scavenge peroxynitrite radicals more effectively than standard antioxidants like Trolox, suggesting their potential in neurodegenerative disease models where oxidative stress plays a key role.

In vaccine development pipelines, DL-arginine hydrochloride has been incorporated into adjuvant formulations to enhance T-cell receptor signaling pathways. Preclinical data from BioRxiv manuscripts indicate that nanoparticulate carriers loaded with this compound induce CD8+ T-cell responses twice as potent as alum-based adjuvants when tested against influenza antigens in murine models.

Synthetic biology approaches are now leveraging this compound’s properties for engineered microbial factories producing non-canonical amino acids. By overexpressing arginase variants coupled with DLA feeding strategies, Escherichia coli strains have achieved unprecedented yields of N^-methyl-D-aspartate (NMDA), critical for studying glutamatergic neurotransmission disorders without resorting to hazardous chemical synthesis routes.

The regulatory landscape surrounding this compound continues evolving as its applications expand beyond traditional realms. Recent FDA draft guidelines emphasize strict impurity profiling requirements (<0.1% N-nitrosodimethylamine) due to emerging concerns about nitrosamine formation during long-term storage under specific humidity conditions (>70% RH). Such regulations underscore the importance of rigorous quality control protocols during both manufacturing and storage phases.

• 627-75-8(D-Arginine hydrochloride)
• 71173-62-1(L-arginine acetate)
• 7200-25-1(DL-Arginine)
• 74-79-3(L-Arginine)
• 332360-01-7(DL-Arginine Hydrochloride Monohydrate)
• 113315-75-6(L-Glutamic acid, polymer with L-alanine and L-arginine)
• 157-06-2(D-Arginine)
• 156-86-5(Homoarginine)
• 32042-43-6(Arginine hydrochloride)
• 1483-01-8(L-Homoarginine Hydrochloride)